Modality
Fusion Protein
MOA
KRASG12Ci
Target
TNFα
Pathway
Apoptosis
Breast Ca
Development Pipeline
Preclinical
~Jul 2010
→ ~Oct 2011
Phase 1
~Jan 2012
→ ~Apr 2013
Phase 2
~Jul 2013
→ ~Oct 2014
Phase 3
~Jan 2015
→ ~Apr 2016
NDA/BLA
~Jul 2016
→ ~Oct 2017
Approved
Jan 2018
→ Nov 2029
ApprovedCurrent
NCT05081634
30 pts·Breast Ca
2018-01→2029-11·Terminated
30 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2029-11-153.6y awayPh3 Readout· Breast Ca
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Termina…
Catalysts
Ph3 Readout
2029-11-15 · 3.6y away
Breast Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05081634 | Approved | Breast Ca | Terminated | 30 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovanaritide | Argenx | Phase 3 | TNFα |